In the current study, RCC cells with wild type (Caki-1 and ACHN) or mutated p53 (786-O and SN12C) show similar sensitivity to DZ-CIS (Fig. 1), as DZ-CIS kills by attacking subcellular organelles, regardless of genetic makeup of the targets. The gene discussed is TP53; the disease is in situ carcinoma.